Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $17.3 million.

  • Amphastar Pharmaceuticals' Net Income towards Common Stockholders fell 5708.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year decrease of 3575.75%. This contributed to the annual value of $148.4 million for FY2024, which is 890.54% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Net Income towards Common Stockholders of $17.3 million as of Q3 2025, which was down 5708.53% from $31.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $49.6 million for Q3 2023, and its period low was $4.0 million during Q1 2021.
  • Its 5-year average for Net Income towards Common Stockholders is $26.8 million, with a median of $26.4 million in 2023.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Net Income towards Common Stockholders soared by 70335.9% in 2021 and then tumbled by 5708.53% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $20.0 million in 2021, then skyrocketed by 46.51% to $29.3 million in 2022, then rose by 14.09% to $33.4 million in 2023, then dropped by 21.4% to $26.2 million in 2024, then tumbled by 33.87% to $17.3 million in 2025.
  • Its last three reported values are $17.3 million in Q3 2025, $31.0 million for Q2 2025, and $25.3 million during Q1 2025.